

under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute the following claim 2 for the pending claim 2:

2. (twice amended) A method for determining whether a compound of interest affects an adenylyl cyclase or phospholipase C pathway and therefore is an agonist or antagonist of a receptor which couples to both Gs and Gq proteins comprising:

- (a) providing a cell line which expresses urokinase-type plasminogen activator (u-PA);
- (b) providing an expression vector comprising a nucleotide sequence encoding for a receptor which couples to both Gs and Gq proteins, said receptor not normally expressed in said cell line of step (a);
- (c) introducing said expression vector into said cell line, thereby providing stably transfected cells;
- (d) contacting said stably transfected cells with said compound of interest; and
- (e) measuring the u-PA activity of the cell culture supernatant of said cells of step (d) by fluorescence or absorbency spectroscopy, thereby

determining whether said compound of interest is an agonist or antagonist
of a receptor which couples to Gq and Gs proteins.